阿立哌唑与喹硫平治疗精神分裂症

Aripiprazole and Quetiapine in Treatment Schizophrenia

目的探讨阿立哌唑与喹硫平治疗精神分裂症的疗效及安全性。方法 84例精神分裂症患者,随机分为对照组及观察组各42例,对照组给予喹硫平治疗,观察组给予阿立哌唑治疗。观察两组治疗前和治疗后2、4、6、8周阳性与阴性症状量表(PANSS)评分和不良反应症状量表(TESS)评分变化。结果两组治疗后与治疗前比较PANSS和TESS减分率的差异均有统计学意义(均P<0.05)。而且,观察组显效更快,在第2、4周PANSS评分显著低于对照组,两组差异有统计学意义(均P<0.05)。结论阿立哌唑与喹硫平治疗精神分裂疗效相当,两药均较为安全,可以改善患者的阳性症状、阴性症状及精神病理评分,但阿立哌唑显效更快。

Objective To evaluate the clinical efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia patients. Methods 84 schizophrenia patients were randomly divided into aripiprazole group （ observation group） or quetiapine group （ control group） for 8 weeks treatment. The efficacy arid adverse reactions was evaluated respectively with positive and negative symptoms scales （PANSS） and treatment emergent symptom scale （TESS） at baseline and after 2^nd , 4^th ,6^th, 8^th week treatment. Results There were significant difference in total scores of PANSS and TESS before and after 8 weeks treatment between the two groups（ all P 〈0.05）. Moreover, the observation group was more effective, PANSS score in the 2^nd ,4^th treatment weeks was significantly lower than the control group （ all P 〈 0.05 ）. Conclusion Aripiprazole and quetiapine had same efficacy and safety to improve the positive symptoms, negative symptoms and psychopathology symptoms of schizophrenia patients, and the aripiprazole had faster clinical efficacy than quetiapine in treatment of schizophrenia.